Telbermin clinical trials
Also written sNN0029.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How each study uses telbermin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses telbermin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot UlcersCompletedPhase 1Genentech, Inc.NCT00069446Written as rhuMAb VEGF (telbermin)
- An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral SclerosisTerminatedPhase 1/2Newron Sweden ABNCT01384162Written as sNN0029
- A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALSTerminatedPhase 1Newron Sweden ABNCT01999803Written as sNN0029
- A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALSTerminatedPhase 1Newron Sweden ABNCT02269436Written as sNN0029 infusion solution
- A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot UlcersCompletedPhase 2Genentech, Inc.NCT00351767Written as telbermin
- A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral SclerosisCompletedPhase 1/2Newron Sweden ABNCT00800501Written as sNN0029
Codes
What other systems call telbermin · ClinicalTrials.gg INT014390
- UNII (FDA) 22G76ZW50XTELBERMINOne source FDA
- NCI Thesaurus C152544TelberminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 22G76ZW50X | TELBERMIN | One source FDA |
| NCI Thesaurus | C152544 | Telbermin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.